BMO Capital Markets set a $8.00 price objective on Atyr Pharma Inc. (NASDAQ:LIFE) in a research report released on Thursday morning. The firm currently has a a hold rating on the stock.

A number of other equities analysts also recently commented on LIFE. Zacks Investment Research downgraded shares of Atyr Pharma from a buy rating to a hold rating in a research note on Wednesday, July 13th. JPMorgan Chase & Co. lowered their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an overweight rating for the company in a research note on Thursday, August 11th. Finally, Citigroup Inc. upped their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a neutral rating in a research note on Tuesday, August 16th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $6.50.

Atyr Pharma (NASDAQ:LIFE) traded down 3.03% during trading on Thursday, hitting $2.88. The company’s stock had a trading volume of 132,749 shares. Atyr Pharma has a one year low of $2.48 and a one year high of $13.26. The firm’s market cap is $68.31 million. The company has a 50-day moving average of $3.15 and a 200 day moving average of $3.30.

Atyr Pharma (NASDAQ:LIFE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.06. On average, equities analysts forecast that Atyr Pharma will post ($2.56) earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in shares of Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock valued at $270,000 after buying an additional 23,290 shares during the period. Jackson Park Capital LLC acquired a new stake in shares of Atyr Pharma during the second quarter valued at $183,000. Emerald Acquisition Ltd. acquired a new stake in shares of Atyr Pharma during the second quarter valued at $206,000. GSA Capital Partners LLP acquired a new stake in shares of Atyr Pharma during the second quarter valued at $101,000. Finally, Vanguard Group Inc. increased its stake in shares of Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock valued at $1,223,000 after buying an additional 240,101 shares during the period. Institutional investors own 44.75% of the company’s stock.

Atyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

5 Day Chart for NASDAQ:LIFE

Receive News & Stock Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related stocks with our FREE daily email newsletter.